Intuitive Surgical Stock Pulls Back to Support – Smart Entry?
Intuitive Surgical (ISRG) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($515.20 – $569.44), levels from which it has bounced meaningfully before. In the last 10 years, Intuitive Surgical stock received buying interest at this level 3 times and subsequently went on to generate 11.7% in average peak returns.
| Peak Return | Days to Peak Return | |
|---|---|---|
| 10/18/2024 | 17.1% | 96 |
| 4/9/2025 | 8.2% | 35 |
| 10/22/2025 | 9.8% | 34 |
Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for ISRG?
ISRG poised for rebound amid innovation & market tailwinds.
Intuitive Surgical’s Q3 2025 revenue surged 23% and procedures grew 20%, driven by da Vinci 5 adoption and recent SP system FDA clearances for hernia, cholecystectomy, and appendectomy. Analysts project a median target price of $603, with Wells Fargo raising its target to $654. The robotic surgery market is expanding at a 14.7% CAGR to $27.14B by 2030, solidifying Intuitive’s leadership despite increasing competition. While valuation remains elevated, updated 2025 guidance of 17-17.5% procedure growth and a recent “golden crossover” technical signal indicate sustained upward momentum.
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- Intuitive Surgical Stock Now 12% Cheaper, Time To Buy
- Better Value & Growth: PODD Leads Intuitive Surgical Stock
- Intuitive Surgical Stock: Join the Rally at a 11% Discount
- Better Value & Growth: PODD Leads Intuitive Surgical Stock
- With Intuitive Surgical Stock Surging, Have You Considered The Downside?
How Do ISRG Financials Look Right Now?
- Revenue Growth: 22.2% LTM and 16.3% last 3-year average.
- Cash Generation: Nearly 23.6% free cash flow margin and 29.3% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for ISRG was 11.7%.
- Valuation: ISRG stock trades at a PE multiple of 58.1
| ISRG | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Health Care Equipment | – |
| PE Ratio | 58.1 | 23.5 |
|
|
||
| LTM* Revenue Growth | 22.2% | 6.0% |
| 3Y Average Annual Revenue Growth | 16.3% | 5.4% |
| Min Annual Revenue Growth Last 3Y | 11.7% | 0.2% |
|
|
||
| LTM* Operating Margin | 29.3% | 18.8% |
| 3Y Average Operating Margin | 26.7% | 18.3% |
| LTM* Free Cash Flow Margin | 23.6% | 13.4% |
*LTM: Last Twelve Months | For more details on ISRG fundamentals, read Buy or Sell ISRG Stock.
And What If The Support Breaks?
ISRG isn’t immune to big drops. It fell 82% during the Dot-Com Bubble and 76% in the Global Financial Crisis. The Inflation Shock saw nearly a 50% dip, and even the Covid sell-off wasn’t mild at 40%. The smaller 2018 correction still knocked it down 24%. So, no matter how strong a stock looks, sharp sell-offs can still hit hard.
But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, outlook changes. Read ISRG Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.
Still not sure about ISRG stock? Consider the portfolio approach.
A Multi Asset Portfolio Beats Picking Stocks Alone
Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices